RT Journal Article
SR Electronic
T1 Predicted domination of variant Delta of SARS-CoV-2 before Tokyo Olympic games, Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.12.21258835
DO 10.1101/2021.06.12.21258835
A1 Ito, Kimihito
A1 Piantham, Chayada
A1 Nishiura, Hiroshi
YR 2021
UL http://medrxiv.org/content/early/2021/06/24/2021.06.12.21258835.abstract
AB Using numbers of SARS-CoV-2 variants detected in Japan, the relative instantaneous reproduction numbers of the R.1, Alpha, and Delta variants with respect to other strains circulating in Japan were estimated at 1.245, 1.437, and 1.948, respectively. The numbers can vary within 1.190–1.319 for R.1, 1.335–1.580 for Alpha, and 1.703–2.30 for Delta depending on the assumed serial interval distributions. The frequency of the Delta is expected to take over the Alpha in Japan around July 12, 2021.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Japan Agency for Medical Research and Development (grant numbers JP20fk0108535). K.I. received funding JSPS KAKENHI (21H03490). P.C. was supported by the World-leading Innovative and Smart Education Program (1801) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. H.N. received funding from Health and Labor Sciences Research Grants (20CA2024 and 20HA2007); the Japan Agency for Medical Research and Development (JP20fk0108140); JSPS KAKENHI (21H03198) and the Japan Science and Technology Agency (JST) SICORP (e-ASIA) program (JPMJSC20U3). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data used for the analysis were provided as Supplementary Table 1.